Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Zostavax® at Minimum Release Specification Approaching Expiry

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: May 16, 2008
Last updated: March 14, 2017
Last verified: March 2017

Primary objective:

To demonstrate whether or not ZOSTAVAX® at minimum release specification approaching expiry potency elicits an acceptable Varicella-Zoster Virus (VZV) antibody fold rise (measured by gpELISA) from pre-vaccination to 4 weeks post-vaccination

Secondary objectives:

To describe the safety profile of ZOSTAVAX® at minimum release specification approaching expiry potency

Condition Intervention Phase
Herpes Zoster
Biological: ZOSTAVAX®
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • geometric mean fold rise (GMFR) of VZV antibody titres from pre- to post-vaccination [ Time Frame: day 28 to day 35 ]

Enrollment: 98
Study Start Date: May 2008
Study Completion Date: October 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: ZOSTAVAX®
    One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain,(live attenuated) not less than 19400 PFU

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject of either gender aged ≥50 years
  • Positive history of varicella or residence for >30 years in a country with endemic VZV infection
  • All females must be postmenopausal or have a negative serum or urine pregnancy test or acceptable method of birth control for three months after vaccination
  • Subject having signed the informed consent form prior to any study procedure

Exclusion Criteria:

  • Subject febrile within 72 hours prior to vaccination
  • Subject with a prior history of Herpes Zoster clinically diagnosed by a physician
  • Subject has previously received a varicella or zoster vaccine
  • Exposure to varicella or herpes-zoster within 4 weeks prior to vaccination
  • Subject received any other live virus vaccine within 4 weeks prior to vaccination, or is expected to receive any other live virus vaccine during the study
  • Subject received any inactivated vaccine within 2 weeks prior to vaccination, or is expected to receive any inactivated vaccine during the study
  • Subject is treated with immunoglobulins or any blood products, other than autologous blood transfusion, given during the 5 months prior to vaccination or is expected to be treated during the study
  • Subject is taking any non topical antiviral therapy with activity against herpesviruses.
  • Subject is on immunosuppressive therapy
  • Subject has known or suspected immune dysfunction caused by a medical condition, or any other cause
  • Subject has a history of hypersensitivity reaction or anaphylactoid reaction to any vaccine component, including gelatin or neomycin
  • Subject with known active tuberculosis
  • Subject with significant underlying illness preventing completion of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00681031

Angers, France
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Anne FIQUET, MD SPMSD
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00681031     History of Changes
Other Study ID Numbers: V211-044
ZTV02C ( Other Identifier: MCMVaccBV (SPMSD) Protocol Number )
Study First Received: May 16, 2008
Last Updated: March 14, 2017

Additional relevant MeSH terms:
Herpes Zoster
Herpesviridae Infections
DNA Virus Infections
Virus Diseases processed this record on May 25, 2017